Notice: This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends TROV vs. FENC, OCGN, IPHA, INMB, PLX, GNFT, CCCC, CRGX, CDTX, and CGENShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Fennec Pharmaceuticals (FENC), Ocugen (OCGN), Innate Pharma (IPHA), INmune Bio (INMB), Protalix BioTherapeutics (PLX), Genfit (GNFT), C4 Therapeutics (CCCC), CARGO Therapeutics (CRGX), Cidara Therapeutics (CDTX), and Compugen (CGEN). These companies are all part of the "medical" sector. Cardiff Oncology vs. Fennec Pharmaceuticals Ocugen Innate Pharma INmune Bio Protalix BioTherapeutics Genfit C4 Therapeutics CARGO Therapeutics Cidara Therapeutics Compugen Fennec Pharmaceuticals (NASDAQ:FENC) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Is FENC or TROV more profitable? Fennec Pharmaceuticals has a net margin of -2.30% compared to Cardiff Oncology's net margin of -3,688.31%. Fennec Pharmaceuticals' return on equity of -53.38% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Fennec Pharmaceuticals-2.30% -53.38% -2.08% Cardiff Oncology -3,688.31%-202.00%-122.92% Does the media favor FENC or TROV? In the previous week, Fennec Pharmaceuticals had 32 more articles in the media than Cardiff Oncology. MarketBeat recorded 32 mentions for Fennec Pharmaceuticals and 0 mentions for Cardiff Oncology. Fennec Pharmaceuticals' average media sentiment score of 0.46 beat Cardiff Oncology's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Fennec Pharmaceuticals Neutral Cardiff Oncology Neutral Do analysts prefer FENC or TROV? Fennec Pharmaceuticals presently has a consensus target price of $13.67, indicating a potential upside of 109.93%. Given Fennec Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Fennec Pharmaceuticals is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, FENC or TROV? Fennec Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Does the MarketBeat Community believe in FENC or TROV? Cardiff Oncology received 200 more outperform votes than Fennec Pharmaceuticals when rated by MarketBeat users. Likewise, 73.09% of users gave Cardiff Oncology an outperform vote while only 66.67% of users gave Fennec Pharmaceuticals an outperform vote. CompanyUnderperformOutperformFennec PharmaceuticalsOutperform Votes20266.67% Underperform Votes10133.33% Cardiff OncologyOutperform Votes40273.09% Underperform Votes14826.91% Which has stronger earnings & valuation, FENC or TROV? Fennec Pharmaceuticals has higher revenue and earnings than Cardiff Oncology. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFennec Pharmaceuticals$47.54M3.77-$16.05M-$0.06-108.50Cardiff Oncology$250K176.18-$16.41M-$2.80-1.43 Do insiders and institutionals have more ownership in FENC or TROV? 55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are owned by institutional investors. 11.0% of Fennec Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryFennec Pharmaceuticals beats Cardiff Oncology on 14 of the 19 factors compared between the two stocks. Remove Ads Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TROV vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.04M$3.08B$5.67B$8.12BDividend YieldN/A1.46%4.40%4.10%P/E Ratio-1.3227.9223.9019.07Price / Sales176.18440.08395.6188.27Price / CashN/A168.6838.1134.64Price / Book4.263.466.834.29Net Income-$16.41M-$71.72M$3.20B$247.56M Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TROVCardiff OncologyN/A$4.00+1.3%N/A-25.9%$44.04M$250,000.00-1.32N/AFENCFennec Pharmaceuticals2.1623 of 5 stars$6.77-3.6%$13.67+101.9%-34.5%$186.60M$49.35M-67.69N/AAnalyst ForecastAnalyst RevisionNews CoverageOCGNOcugen0.9865 of 5 stars$0.61-7.2%$6.00+891.6%-50.3%$176.28M$4.70M-3.3680IPHAInnate Pharma2.4982 of 5 stars$2.09-1.4%$11.50+450.2%-20.1%$175.21M$24.85M0.00220Short Interest ↑News CoverageINMBINmune Bio1.9457 of 5 stars$7.74-3.6%$22.80+194.6%-28.1%$171.61M$42,000.00-3.5510PLXProtalix BioTherapeutics2.3005 of 5 stars$2.31-0.9%$15.00+549.4%+68.4%$170.10M$45.67M-17.77200Analyst UpgradeNews CoverageHigh Trading VolumeGNFTGenfit1.9386 of 5 stars$3.40-2.0%$13.00+282.4%-0.1%$169.99M$76.06M0.00120Positive NewsHigh Trading VolumeCCCCC4 Therapeutics2.1041 of 5 stars$2.40-11.4%$12.50+420.8%-77.3%$169.41M$33.67M-1.41150Gap DownCRGXCARGO Therapeutics3.1502 of 5 stars$3.68-2.1%$15.00+307.6%-86.5%$169.38MN/A-0.86116Analyst RevisionCDTXCidara Therapeutics4.3677 of 5 stars$23.05-7.4%$32.20+39.7%+61.0%$162.43M$44.65M-0.9090Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageCGENCompugen1.8493 of 5 stars$1.81-5.7%$4.00+121.0%-39.6%$161.52M$59.85M90.5070Positive News Remove Ads Related Companies and Tools Related Companies FENC Competitors OCGN Competitors IPHA Competitors INMB Competitors PLX Competitors GNFT Competitors CCCC Competitors CRGX Competitors CDTX Competitors CGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TROV) was last updated on 3/16/2025 by MarketBeat.com Staff From Our PartnersForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | Sponsored[Revealed] Trump’s Plan to Protect Your Savings for the Deep StateDuring Trump's first term, gold skyrocketed 52.89%. And it's already surging before his second. Last yea...Genesis Gold Group | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TROV Stock Alerts